ArticlePloS one2016
Diffusion Retardation by Binding of Tobramycin in an Alginate Biofilm Model.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 69 citations in OpenAlex.
- Article
- Microplastics as active modulators ofBiofilm · 2026Article
- Berberine Interferes with the Molecular Landscape of Biofilm-Driven Pathogenicity.Pathogens (Basel, Switzerland) · 2026Review
- Quantification of Antibiotic Diffusion in Biofilms Using Gold Nanostar Surface-enhanced Raman Spectroscopy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Beyond the matrix: rethinking antibiotic tolerance in CF biofilms using 3D models.NPJ biofilms and microbiomes · 2025Article
- Role of gene PA2798 on biofilm formation and virulence factors production of Pseudomonas aeruginosa.Folia microbiologica · 2025Article
- Is Increased Biofilm Formation Associated with Decreased Antimicrobial Susceptibility? A Systematic Literature Review.Microorganisms · 2025Review
- Mechanistic insights and therapeutic innovations in engineered nanomaterial-driven disruption of biofilm dynamics.RSC advances · 2025Review
- Diversification ofMicroorganisms · 2025Article
- Targeting AI-2 quorum sensing: harnessing natural products against Streptococcus suis biofilm infection.Veterinary research · 2025Article
- Review
- Intestinal biofilms: pathophysiological relevance, host defense, and therapeutic opportunities.Clinical microbiology reviews · 2024Review
- Effect of biofilm physical characteristics on their susceptibility to antibiotics: impacts of low-frequency ultrasound.NPJ biofilms and microbiomes · 2024Article
- Article
- Hyperbaric oxygen therapy counteractsBiofilm · 2023Article
- Mechanisms of antibiotic resistance inBiofilm · 2023Article
- Biofilm tolerance, resistance and infections increasing threat of public health.Microbial cell (Graz, Austria) · 2023Review
- Determining effects of nitrate, arginine, and ferrous on antibiotic recalcitrance of clinical strains of Pseudomonas aeruginosa in biofilm-inspired alginate encapsulates.Annals of clinical microbiology and antimicrobials · 2023Article
- Article
- Inoculum Concentration Influences Pseudomonas aeruginosa Phenotype and Biofilm Architecture.Microbiology spectrum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial cells embedded in a self-produced extracellular biofilm matrix cause chronic infections, e. g. by Pseudomonas aeruginosa in the lungs of cystic fibrosis patients. The antibiotic killing of bacteria in biofilms is generally known to be reduced by 100-1000 times relative to planktonic bacteria. This makes such infections difficult to treat. We have therefore proposed that biofilms can be regarded as an independent compartment with distinct pharmacokinetics. To elucidate this pharmacokinetics we have measured the penetration of the tobramycin into seaweed alginate beads which serve as a model of the extracellular polysaccharide matrix in P. aeruginosa biofilm. We find that, rather than a normal first order saturation curve, the concentration of tobramycin in the alginate beads follows a power-law as a function of the external concentration. Further, the tobramycin is observed to be uniformly distributed throughout the volume of the alginate bead. The power-law appears to be a consequence of binding to a multitude of different binding sites. In a diffusion model these results are shown to produce pronounced retardation of the penetration of tobramycin into the biofilm. This filtering of the free tobramycin concentration inside biofilm beads is expected to aid in augmenting the survival probability of bacteria residing in the biofilm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.